TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35054157
Drug: Standard vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vitamin preparations (2500 IU vitamin A, 1428 IU beta-carotene, 4000 IU D3, 150 IU E, 2.14 mg K1)
Study: 33049119
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide (500 µg in 0.9% saline per dose)
Study: 33185345
Drug: Sildenafil spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil spray (50 mg) on an empty stomach
Study: 33185345
Drug: Sildenafil tablet
Normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil tablet (50 mg) on an empty stomach
Study: 33185345
Drug: Sildenafil spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil spray (50 mg) after a meal
Study: 33185345
Drug: Sildenafil tablet
Normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil tablet (50 mg) after a meal
Study: 33420114
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of hepatitis A vaccine (0, 6 months)
Study: 33420114
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen of hepatitis A vaccine (0, 1, 6 months)
Study: 32368869
Drug: Lenabasum (cannabinoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum (cannabinoid type 2 receptor agonist)
Study: 33690245
Drug: Fully automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully automated pulsating support system air mattress used for 30 days in the treatment group (n = 18)
Study: 36173596
Drug: Colchicine (1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1-1.5 mg/day for 3 days, then 0.5 mg/day for 11 days) and Prednisone (60 mg/day for 3 days)
Study: 36173596
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (intravenous dexamethasone)
Study: 35361560
Drug: Intermittent fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent fasting (water-only 24-h fasting twice-per-week for 4 weeks and once-per-week for 22 weeks)
Study: 32659313
Drug: DBV712 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBV712 250 μg (epicutaneous immunotherapy)
Study: 36807273
Drug: Conventional drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug-eluting stent (DES)
Study: 33634616
Drug: 0.8% HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% HA gel
Study: 34694643
Drug: Placebo tendoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tendoscopic treatment
Study: 33220329
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g MCT/day
Study: 33220329
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g MCT/day
Study: 33220329
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g MCT/day)
Study: 33220329
Drug: MCT (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT (12 g and 18 g)
Study: 32002593
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg adrenaline via intraosseous route
Study: 32002593
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg adrenaline via intravenous route
Study: 34489390
Drug: Extended-field IMRT
Normalized name: ZINC OXIDE 17.8 g in 100 mL TOPICAL LOTION [Fieldtrip - Whatever the Weather Daily Moisturizer Zinc Oxide Sunscreen - SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-field IMRT with chemotherapy
Study: 34489390
Drug: Pelvic-field IMRT
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic-field IMRT with chemotherapy
Study: 36171582
Drug: Hydrocortisone 200
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 200 mg daily, vitamin C 2 g every 6 hours, thiamine 200 mg every 12 hours
Study: 33185364
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide 0.1 mg
Study: 33185364
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide 0.2 mg
Study: 33185364
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide 0.4 mg
Study: 32444056
Drug: Diphenhydramine solution
Normalized name: diphenhydramine Oral Solution
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine solution (DS)
Study: 32515694
Drug: PIV ≤
Normalized name: Piperacillin/tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIV ≤ 7 mL (25th percentile)
Study: 32515694
Drug: PIV ≥
Normalized name: Piperacillin/tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIV ≥ 72 mL (75th percentile)
Study: 32515694
Drug: Pre-treatment factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment factors for small-PIV/mRS ≥ 3
Study: 32515694
Drug: Post-treatment factors
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment factors for small-PIV/mRS ≥ 3
Study: 32859308
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (ESPEN)
Study: 32859308
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (ASPEN)
Study: 35778995
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) using ropivacaine, epinephrine, ketorolac, and normal saline solution.
Study: 33944875
Drug: Half-dose csDMARDs
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose csDMARDs (n=80)
Study: 33944875
Drug: Stable-dose csDMARDs
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable-dose csDMARDs (n=80)
Study: 35986131
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Mothers and Babies (MB) intervention (attendance at >50% of MB sessions)
Study: 35986131
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of Mothers and Babies (MB) intervention
Study: 36214216
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg ensovibep
Study: 36214216
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ensovibep
Study: 33721561
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (n=644)
Study: 33721561
Drug: Chemotherapy (n=749)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (n=749)
Study: 33721561
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (n=748)
Study: 33721561
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in women aged ≤50 years (n=464)
Study: 33721561
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy in women aged ≤50 years (n=464)
Study: 33721561
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in women aged >50 years (n=894)
Study: 33721561
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy in women aged >50 years (n=894)
Study: 33721561
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in node-negative patients (n=699)
Study: 33721561
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy in node-negative patients (n=699)
Study: 33721561
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with 1-3 positive nodes (n=658)
Study: 33721561
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy in patients with 1-3 positive nodes (n=658)
Study: 33144321
Drug: Anti-N antibodies
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-N antibodies
Study: 32404126
Drug: Solution Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution Focused Brief Therapy (SFBT), 2-4 sessions
Study: 33438238
Drug: Biological determinist
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological determinist message
Study: 35330830
Drug: Neostigmine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.2 mg/h for 120 h)
Study: 32990529
Drug: Dry Needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Needling with Intramuscular Electrical Stimulation (DN/IMES)
Study: 32048316
Drug: Nurse-led supportive
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led supportive intervention, details on dosage and duration not specified.
Study: 32971161
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of celery seed, 3 times a day for 6 weeks
Study: 32971161
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of celery seed
Study: 33903890
Drug: Single hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single hyperbaric oxygen treatment
Study: 32885585
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg thrice daily + 150 mg/day CC for 5 days
Study: 34670665
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) at IC50 (3.586 mg/L) for 48 hours
Study: 34670665
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) at IC50 (3.586 mg/L) combined with 20 μmol/L PD98059 for 48 hours
Study: 34670665
Drug: 20 μmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μmol/L PD98059 for 48 hours
Study: 34942135
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg/day orally)
Study: 33726841
Drug: MEDPass administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MEDPass administration of ONS (50 ml four times per day)
Study: 33726841
Drug: Conventional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional administration of ONS (between meals)
Study: 33726841
Drug: MEDPass administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MEDPass administration of ONS
Study: 34238381
Drug: SLC45A2 rs183671-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLC45A2 rs183671-G allele
Study: 35322474
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (20 mL of 0.375% ropivacaine and 0.5 mcg/kg of clonidine)
Study: 35322474
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (150 mcg preservative-free morphine with 2 mL of normal saline)
Study: 36088901
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (1,000 mg in total)
Study: 36088901
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid (500 mg in total)
Study: 34914232
Drug: Microsurgical varicocelectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical varicocelectomy followed by oral administration of Danhong Tongjing Prescription (DTP) for 90 days
Study: 33043615
Drug: Pelvic EBRT
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic EBRT combined with chemotherapy; 61% for Stage IIIA cases, 88% for IIIC1 cases.
Study: 38013135
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant treatment
Study: 35166029
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser + topical triamcinolone (TA)
Study: 33640890
Drug: Low-dose hydroxychloroquine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydroxychloroquine therapy
Study: 33039952
Drug: DMB (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMB (vitamin D3 1000 IU/d, magnesium 150 mg/d, vitamin B12 500 mcg/d)
Study: 35033180
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of PCV at 6 weeks with a booster at 9 months (1+1 schedule)
Study: 35033180
Drug: Three primary
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three primary doses of PCV at 6, 10, and 14 weeks (3+0 schedule)
Study: 35033180
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of PCV with yellow fever vaccine at 9 months
Study: 33164984
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) treatment (1 g/m2)
Study: 33164984
Drug: Multivariable model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivariable model including ALL subtype, SLC19A1/(ABCC1 + ABCC4) transporter ratio, MTX infusion time, FPGS mRNA expression, and MTX systemic clearance
Study: 33164984
Drug: Longer infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Longer infusion time (24 h vs. 4 h)
Study: 32873926
Drug: Continuous energy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous energy restriction (CER) - 75% energy requirements daily
Study: 36166026
Drug: Serplulimab plus
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab plus chemotherapy (4.5 mg/kg intravenously every 3 weeks)
Study: 36166026
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (intravenously every 3 weeks)
Study: 37215110
Drug: Serplulimab plus
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab plus chemotherapy
Study: 33957881
Drug: Alternate-day oral
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day oral administration of S-1 (80 mg/m2/day) for 4 days a week (Group A)
Study: 33957881
Drug: 2-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week oral administration of S-1 (80 mg/m2/day) followed by 1 week of rest (Group B)
Study: 32007688
Drug: Serum PCDD/Fs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PCDD/Fs (fg TEQ/g lipid)
Study: 33522931
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg oral arm
Study: 34559992
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg on day 1, followed by 5 mg/kg per day on days 2-5)
Study: 33812497
Drug: Chemotherapy (mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (mFOLFOX6 or FOLFIRI)
Study: 33119613
Drug: Rintatolimod treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rintatolimod treatment in the Target Subset (n = 75)
Study: 36310098
Drug: Long intervals
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long intervals (L‐INT; n = 7)
Study: 35637624
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg CBD
Study: 37802088
Drug: Efruxifermin 28
Normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efruxifermin 28 mg
Study: 38447814
Drug: Efruxifermin 50
Normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efruxifermin 50 mg
Study: 34239138
Drug: Efruxifermin 70
Normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efruxifermin 70 mg
Study: 34798295
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Methylnaltrexone (MNTX) administered perioperatively
Study: 34825104
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) applied in the first 10–15 min of each Physical Education class, twice a week for 16 weeks, with 14 to 20 all-out bouts intervals and a 2:1 work to rest ratio.
Study: 35964210
Drug: Robotic-assisted gait
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted gait training (30 minutes) + conventional physical therapy (30 minutes)
Study: 35964210
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (60 minutes)
Study: 32943843
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg, then 2 mg/kg/h, IV)
Study: 32818325
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour group therapy (CBGT)
Study: 35469428
Drug: LT4 oral
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 15 minutes before a high-fat high-calorie meal
Study: 35469428
Drug: LT4 oral
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 30 minutes before a high-fat high-calorie meal
Study: 34582369
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg/d)
Study: 35007127
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (InO) 0.8 mg/m2 intravenously on day 1 and 0.5 mg/m2 on days 8 and 15 of a 28-day cycle.
Study: 34143803
Drug: Nguvu intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nguvu intervention (8 weekly sessions delivered by lay refugee incentive workers)
Study: 34212187
Drug: Standard 12-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 12-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor
Study: 35339652
Drug: Massage chair
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage chair used twice a day for 6 months
Study: 32665039
Drug: Hydroxychloroquine 400mg
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 400mg orally once daily for 90 days
Study: 32665039
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets visually identical to hydroxychloroquine) orally once daily for 90 days
Study: 616115985
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily (n=44)
Study: 36031355
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg (group M)
Study: 36031355
Drug: Dexmedetomidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.5 μg/kg (group H)
Study: 36031355
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg (group L)
Study: 32019389
Drug: Dance intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance intervention (twice-weekly sessions for 8 months)
Study: 32931958
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy
Study: 36148447
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (RM) only
Study: 35036624
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) once monthly for 6 months
Study: 33544206
Drug: 16 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g/d native inulin (prebiotic)
Study: 33494132
Drug: Aronia juice
Normalized name: Aronia melanocarpa fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia juice (AJ) with 1177.11 mg polyphenols/100 mL (n = 22)
Study: 33494132
Drug: Aronia juice
Normalized name: Aronia melanocarpa fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia juice (MJ) with 294.28 mg polyphenols/100 mL (n = 20)
Study: 34052458
Drug: Health literacy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health literacy evaluation using the Rapid Estimate of Adult Literacy in Medicine (REALM)
Study: 35648294
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg implanted into the socket
Study: 33431491
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of CNM-Au8 once daily for 36 weeks
Study: 32998143
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg monotherapy
Study: 32998143
Drug: Eplerenone/Ramipril 50/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone/Ramipril 50/10 mg combination therapy
Study: 36123724
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate injection (2 ml)
Study: 36123724
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (2 ml)
Study: 33045140
Drug: Intranasal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal capsaicin 0.1mM